A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE EFFECTS OF DOCOSAHEXAE

DOCOSAHEXAE 作用的随机双盲安慰剂对照试验

• 批准号: 7951056
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.96万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951056
• 关键词: Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animals; Antioxidants; Asses; Blood; Brain; Cerebrospinal Fluid; Clinical Research; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Diet Habits; Dietary intake; Docosahexaenoic Acids; Epidemiologic Studies; Funding; Grant; Gray unit of radiation dose; Hippocampus (Brain); Human; Individual; Institution; Memory; Micronutrients; Mus; Omega-3 Fatty Acids; Phospholipids; Placebos; Plasma; Randomized; Rattus; Research; Research Personnel; Resources; Sampling; Source; Supplementation; Testing; Thinking; United States National Institutes of Health; Urine; double-blind placebo controlled trial; functional decline; human subject

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epidemiological studies show that Docosahexaenoic Acid (DHA) supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate Alzheimer s Disease (AD). DHA, an omega-3 fatty acid has been shown to reduce brain levels of beta-amyloid (A¿) in mice and rat models of AD, as well as have antioxidant effects on the cerebrospinal fluid. Individuals with AD have significantly decreased brain levels of DHA in frontal grey and hippocampus phospholipids compared to controls (as seen in previous human studies), as well as significantly lower plasma levels of DHA compared to control subjects. Since dietary intake of DHA can increase plasma levels of DHA in human subjects, and since dietary intake and plasma levels correlate with brain levels in animals, treatment of AD with DHA supplementation is plausible, and thus proposed in this study. This study will evaluate the effects of DHA versus placebo in subjects with mild to moderate AD over an 18 month period by administering memory and thinking tests. Blood and urine samples will also be collected in this study to examine the micronutrients related to dietary habits which may reveal DHA effects.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 流行病学研究表明，在18个月的时间里，补充二十二碳六烯酸可以减缓轻到中度阿尔茨海默病患者S病(AD)认知和功能下降的进程。DHA是一种omega-3脂肪酸，已被证明可以降低AD模型小鼠和大鼠大脑中的β-淀粉样蛋白(A？)水平，并对脑脊液具有抗氧化作用。与对照组相比，阿尔茨海默病患者大脑前额叶灰质和海马磷脂中的DHA水平显著降低(如先前的人类研究所见)，血浆中DHA的水平也显著降低。由于膳食摄入DHA可以增加受试者的血浆DHA水平，而且膳食摄入和血浆水平与动物的脑水平相关，因此补充DHA治疗AD是可行的，因此本研究提出了这一建议。 这项研究将通过实施记忆和思维测试，在18个月的时间里评估DHA与安慰剂在轻中度AD患者中的效果。这项研究还将收集血液和尿样，以检查与饮食习惯有关的微量营养素，这可能会揭示DHA的影响。